Genocea Biosciences (NASDAQ:GNCA)

CAPS Rating: 3 out of 5

Results 1 - 1 of 1


Member Avatar zzlangerhans (99.71) Submitted: 5/27/2015 4:07:01 PM : Outperform Start Price: $10.51 GNCA Score: -40.48

Genocea can't seem to get any respect from the street, even after reporting a 55% reduction from baseline in viral shedding from the phase II trial of their genital herpes vaccine. Perhaps that because all groups including the placebo group reported a stat sig reduction in genital lesion rates from baseline. That seems to indicate the company doesn't know how to design a reliable trial. Enrollment is complete in phase II trial of GEN-004 universal pneumococcal vaccine for pneumococcal infections with topline data expected in Q4 2015. Hopefully the company won't report a significant decline in pneumococcal infections in the placebo group of that trial. Given the market cap of about 250M and 84M in cash as of the end of Q1, I'll make a cautious bet that the next leg will be back upward.

Results 1 - 1 of 1

Featured Broker Partners